ArticleClinical case reports2026
Structural Restoration of an Unruptured Vertebral Artery Dissection Following Autologous Mesenchymal Stem Cell Therapy: A Case Report.
Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vertebral artery dissection (VAD) is a recognized cause of ischemic stroke, and current management relies on antithrombotic therapy that is not specifically directed at structural repair of the arterial wall. We report a man in his mid-50s who presented with a sudden, severe right occipital headache after a golf swing and had a history of a contralateral left VAD 16 years earlier. High-resolution vessel wall magnetic resonance imaging and angiography showed an acute, unruptured dissection of the right V4 segment with an intramural hematoma, and serial imaging documented progression of the true-lumen stenosis before treatment. Because the lesion was progressing and stenting of the intracranial V4 segment carried a high risk of iatrogenic rupture, autologous bone marrow-derived mesenchymal stem cells (MSCs) were administered as a well-tolerated adjunct to continued antithrombotic therapy, in two systemic infusions at 8 weeks and 10 months after onset. The patient had an uneventful clinical course with no infusion-related adverse events, and follow-up imaging at 11 months showed resorption of the intramural hematoma and restoration of a normal-appearing lumen and wall. Because spontaneous healing of unruptured VAD cannot be excluded, this single, uncontrolled observation cannot establish that MSC therapy caused the recovery; nonetheless, the treatment was well-tolerated and the favorable course warrants evaluation in adequately controlled studies before any therapeutic role of MSCs in VAD can be defined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.